![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif)
prinomastat A synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif)
Code name: | ![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif) | AG3340 | | ![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure name: | ![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif) | (3S)-N-hydroxy-2,2-dimethyl-4-{{4-(4-piridinyloxy)phenyl}sulfonyl}-3-thiomorpholinecarboxamide | | ![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/web/20090115001732im_/http://www.cancer.gov/images/spacer.gif) |